SNMMI annual meeting featured a clinical diagnosis and therapy session and a presentation by Dr. Kambiz Rahbar discussing the clinical value of the PROSTest to detect biochemical recurrence in ...

SNMMI annual meeting featured a clinical diagnosis and therapy session and a presentation by Dr. Kambiz Rahbar discussing the utility of the PROSTest to predict response to 177 Lu-PSMA therapy in ...

Trimodality therapy (TMT), consisting of maximal transurethral resection of bladder tumor (TURBT) followed by concurrent chemoradiotherapy, has emerged as a bladder-sparing alternative to radical ...

Zachary Klaassen speaks with Oliver Sartor about treatment intensification in metastatic hormone-sensitive prostate cancer, focusing on triplet therapy selection. Dr. Sartor traces the evolution from ...

Previous research on Radium-223 treatment patterns in metastatic prostate cancer has been limited to select sites, oncology practices, or claims databases. Limited data exists on the use and outcomes ...

Leslie Ballas speaks with Timothy Showalter about a multimodal artificial intelligence-based prostate cancer test. Dr. Showalter explains how ArteraAI analyzes H&E-stained biopsy slides using computer ...

PDIGREE phase III adaptive, enrolled 1000+ metastatic kidney cancer patients across 500+ sites, ASCO 2025 results and innovative treatment strategies, PDIGREE Trial Tests Adaptive Immunotherapy ...

Enfortumab vedotin (EV) in combination with pembrolizumab (P) has led to a new paradigm for the treatment of metastatic urothelial carcinoma (mUC). Since the presentation of the results of the EV-302 ...

None of the ongoing phase 3 trials are evaluating the impact of the adjuvant component of perioperative PD1/PDL1 inhibition combined with neoadjuvant chemotherapy for muscle-invasive bladder cancer.

Sam Chang interviews Alice Yu about three practice-changing areas in urothelial carcinoma. Dr. Yu first discusses the NIAGARA trial, which demonstrated improved pathologic complete response, ...

May 16, 2025 Biochemical recurrence (BCR) after radical prostatectomy exhibits heterogeneous prognostic implications. Recent advancements in imaging and biomarkers have high potential for ...

PSMAfore trial results, significant radiographic progression-free survival benefit with PLUVICTO versus secondary ARPIs in pre-chemotherapy mCRPC patients, Lutetium-177 PSMA Radioligand Therapy ...